Compare MTX & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTX | DVAX |
|---|---|---|
| Founded | 1968 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 1992 | 2004 |
| Metric | MTX | DVAX |
|---|---|---|
| Price | $67.59 | $15.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 5 |
| Target Price | ★ $79.67 | $26.50 |
| AVG Volume (30 Days) | 167.2K | ★ 5.6M |
| Earning Date | 01-29-2026 | 02-19-2026 |
| Dividend Yield | ★ 0.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,071,200,000.00 | $330,514,000.00 |
| Revenue This Year | N/A | $24.63 |
| Revenue Next Year | $4.02 | $15.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 26.73 |
| 52 Week Low | $49.54 | $9.20 |
| 52 Week High | $78.23 | $15.73 |
| Indicator | MTX | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 72.08 | 85.75 |
| Support Level | $65.82 | $15.57 |
| Resistance Level | $68.24 | $15.73 |
| Average True Range (ATR) | 1.59 | 0.06 |
| MACD | 0.40 | -0.05 |
| Stochastic Oscillator | 87.42 | 70.83 |
Minerals Technologies Inc mines, produces, and sells mineral-based products. The firm organizes itself into two segments: The Consumer & Specialties segment that derives maximum revenue, serves consumer end markets directly with mineral-to-market finished products and also provides specialty mineral-based solutions and technologies that are an essential component of its customers' finished products. The Engineered Solutions segment serves industrial end markets with engineered systems, mineral blends, and technologies that are designed to improve its customers' manufacturing processes and projects. The majority of revenue comes from the United States.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.